Academic Journals Database
Disseminating quality controlled scientific knowledge

Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility Study

Author(s): Z. Einbeigi | D. Bergström | T. Hatschek | M. Malmberg

Journal: Clinical Medicine : Oncology
ISSN 1177-9314

Volume: 2;
Start page: 533;
Date: 2008;
Original page

Keywords: epirubicin | paclitaxel | capecitabine | first-line chemotherapy | metastatic breast cancer | phase I/II

Thirteen patients with untreated metastatic breast cancer received epirubicin 60 mg/m2, paclitaxel 155 mg/m2 (both day 1) and capecitabine 665 mg/m2 twice daily (days 1–14) every 21 days, with intra-patient dose escalation/reduction. Grade 3/4 events were infrequent. Nine patients (69%) achieved an objective response. Median time to progression and overall survival were 6.6 and 23.5 months, respectively.
RPA Switzerland

Robotic Process Automation Switzerland


Tango Jona
Tangokurs Rapperswil-Jona